Healthcare
Progyny, Inc.(PGNY)
Live Price
Offline$26.08
-0.87% today
1Y Change
+25.44%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $1.52B
- Revenue Growth
- +10.4%
- EPS Growth
- +15.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Progyny, Inc. (PGNY) is a Healthcare stock with a market cap of $1.52B and listed on NASDAQ. The stock last traded around $26.08 and up 25.4% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +10.4%, EPS growth of +15.3%, a dividend yield of 0.0%. What stands out right now is revenue +10.4%, EPS +15.3%, free cash flow +10.4% with operating margin 6.6% and ROIC 9.6%. Valuation is more restrained than many high-expectation growth names at P/E 27.1 and price/sales 1.2. Stock Foundry combines PGNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.4% vs +7.6% peer median
Operating Margin
Below sector median
+6.6% vs +19.4% peer median
P/E
Below sector median
27.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 7, 2026 with an EPS surprise of +13.3% and a revenue surprise of +0.6%.
The operating story is still moving forward
Revenue is running at +10.4% and EPS at +15.3%, with operating margin around 6.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +11.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | +13.3% | +23.8% | +19.4% | +35.0% |
2026 Feb 26, 2026 | +2.0% | -20.5% | -20.8% | -20.0% |
2025 Nov 6, 2025 | +15.4% | +24.2% | +35.6% | +33.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PGNY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PGNY Max Drawdown
-42.65%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PGNY and SPY.
Company Overview
Progyny, Inc.
NASDAQ Global Select
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
- Leadership
- David J. Schlanger
- IPO Date
- Oct 25, 2019
- Employees
- 675
- Street Address
- 1359 Broadway
- Mailing
- New York City, NY, 10018
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 888 3124
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 27.1
- EV/EBITDA
- 14.7
- Price/Sales
- 1.2
- Price/Book
- 3.1
Growth
- Revenue
- +10.4%
- EPS
- +15.3%
- Free Cash Flow
- +10.4%
Profitability
- Gross Margin
- 23.6%
- Operating Margin
- 6.6%
- Net Margin
- 4.5%
- ROE
- 11.4%
- ROIC
- 9.6%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 2.73
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.